New ICH Guideline Q14 on Analytical Procedure Development – Implications for Gonadotropin API Manufacturers

The International Council for Harmonisation (ICH) recently finalized Q14, which emphasizes enhanced analytical method development and lifecycle management. For gonadotropin manufacturers – whether urinary or recombinant – this means tighter control over purity profiles, impurity characterization, and assay validation. Companies supplying crude or intermediate grades should prepare to provide more detailed analytical data to downstream formulators. Early adoption of Q14-aligned methods can become a competitive differentiator for API suppliers aiming at regulated markets.